"This study was obviously done prior to June of 2013 as they refer to the company being in a Phase II study and here we are 3 and a half years later reading about this study. It was published 30 Nov 2017. The BoM trial was not even mentioned."

This study was submitted in June 2017. Even IF the research began in 2013, the write up for publication is the last step. They cite several papers from 2016 and a couple from 2017, including the Atherosclerosis 2016 paper on the Phase 2 apabetalone ASSURE/SUSTAIN pooled analysis. So clearly, they wrote the paper recently. I think they simply failed to do their research on Clinical Trials and simply went off of published papers. Nothing on BETonMACE isn't published. Only Phase 2 apabetalone studies are published.

"What's even more interesting is that this study was well before Hepalink got involved with us and the study was done in Shanghai. This now brings up another thought that someone on this board posted about over the last couple of months, has someone from Hepa or close to them been doing all kinds of testing with RVX208 on their own for a number of yrs now?"

Yes, done in Shanghai. But as stated above, you have no idea when it started. Just because they weren't aware of ongoing BETonMACE Phase 3 trial doesn't mean that this study was done prior to the initial Hepalink involvement. As for Hepalink or "someone close to them" doing "all kinds of testing"......pre-clinical research maybe. But I don't buy the argument that they are performing secret human clinical trials with apabetalone. That's just paranoid speculation in my opinion.

"Don't know about a cure for obsessing or hair loss but I did hear, in one of the small group discussions at an AGM of years gone by, that if RVX208 was successful at regressing plaque it could make your member stand at attention the way it did when you were 18. Wow this could be a rock solid investment."

Careful there Tada. You are close to getting a stiff penalty from Agoracom for that. LOL.

To be honest, this area of research isn't my specialty, but based upon publication titles and glancing at the abstracts....the use of BET inhibitors to reactivate HIV from latency is not new. I think I saw papers from 2013 showing that pan-BET inhibitors elicit similar effects as what is shown in this paper. However, what is novel in my opinion is showing that a bromodomain-2 selective BET inhibitor (RVX-208; apabetalone) can do what pan-BET inhibitors were previously shown to do for reactivating HIV from latency.